Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

BACKGROUND: Although targeted therapies have improved the clinical outcomes of cancer treatment, tumors resistance to targeted drug are often detected too late and cause mortality. CSE1L is secreted from tumor and its phosphorylation is regulated by ERK1/2. ERK1/2 is located downstream of various gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Woan-Ruoh, Shen, Shing-Chuan, Shih, Yi-Hsien, Chou, Chia-Lun, Tseng, Jonathan Te-Peng, Chin, Szu-Ying, Liu, Kao-Hui, Chen, Yen-Chou, Jiang, Ming-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467675/
https://www.ncbi.nlm.nih.gov/pubmed/26070816
http://dx.doi.org/10.1186/s12967-015-0553-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467675/
https://www.ncbi.nlm.nih.gov/pubmed/26070816
http://dx.doi.org/10.1186/s12967-015-0553-6

Ejemplares similares